OncoMatch/Clinical Trials/NCT06036745
Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen
Is NCT06036745 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Pembrolizumab + SOX for gastric cancer stage iiib-iiic.
Treatment: Pembrolizumab + SOX — it is an an Exploratory Single-Arm, Single-Center Study of Pembrolizumab in Combination with SOX Regimen for Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Gastric Cancer
Biomarker criteria
Required: MSI high-frequency microsatellite instability
Consistent with high-frequency microsatellite instability MSI-H
Required: PD-L1 (CD274) high expression (CPS score ≥5)
High expression of PD-L1 (CPS score ≥5)
Disease stage
Required: Stage IIIB, IIIC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Must have received: surgery — adjuvant
after radical resection
Cannot have received: anti-tumor immunotherapy
Have not received anti-tumor immunotherapy
Lab requirements
Blood counts
hemoglobin ≥90g/l; absolute neutrophil count ≥1.5×109/ l; platelet count ≥100×109/ l
Liver function
aspartate or alanine aminotransferase ≤ 2.5 times the upper limit; alkaline phosphatase ≤ 2.5 times the upper normal limit
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06036745 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anti-tumor immunotherapy disqualifies patients from enrollment.
Does this trial require MSI?
Yes, MSI high-frequency microsatellite instability is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 high expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages